Precigen, Inc. (PGEN) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Precigen, Inc. (PGEN) posted $9.68M in revenue for fiscal 2025 (up 146.7% year over year), with a net loss of $250.64M, and has compounded revenue about -21.3%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Precigen, Inc.
Precigen, Inc. has grown revenue from $190.93M to $9.68M over the last 10 fiscal years, compounding about -21.3% a year. The most recent year was up 146.7%, so growth is actually accelerating.
Net margin sits at -2588.2%, up 628 points year over year on a 50.2% gross margin. It carries about $93.17M of total debt.
The one thing worth a second look in the filings is receivables growing faster than sales.
Synthesised from Precigen, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Precigen, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.93M | $230.98M | $151.18M | $90.72M | $31.99M | $14.27M | $26.91M | $6.22M | $3.92M | $9.68M |
| Gross profit | $153.22M | $197.72M | — | — | — | — | $20.57M | $106,000 | $-342,000 | $4.86M |
| Net income | $-186.61M | $-117.02M | $-509.34M | $-322.32M | $-170.52M | $-92.17M | $28.32M | $-95.90M | $-126.23M | $-250.64M |
| Net margin | -97.7% | -50.7% | -336.9% | -355.3% | -533.0% | -646.0% | 105.2% | -1540.6% | -3216.2% | -2588.2% |
Source: Precigen, Inc. SEC filings (10-K). 15 years of history available in the interactive view.
Precigen, Inc.: 4 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Receivables growing faster than salesAccounts receivable rose 275.1% while revenue rose 146.7% in the latest year — a gap that can signal looser credit terms or pulled-forward sales. Worth checking days-sales-outstanding.
- Share count rising (dilution)Shares outstanding grew 71.2% over 4 years (206.7M → 353.9M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $93.2M of debt while last year's operating cash flow was negative ($-87.8M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -2588.2%).
Explore 15 years of Precigen, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PGEN in your portfolio →
Precigen, Inc. financial history by metric
About Precigen, Inc.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Precigen, Inc. — frequently asked questions
What is Precigen, Inc.'s revenue?
Precigen, Inc. (PGEN) reported revenue of $9.68M for fiscal year 2025, up 146.7% from the prior year, according to its SEC filings.
Is Precigen, Inc. profitable?
No — PGEN reported a net loss of $-250.64M in fiscal 2025.
What is PGEN's P/E ratio?
Precigen, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Precigen, Inc. growing?
PGEN's revenue grew at roughly -21.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Precigen, Inc. have?
As of fiscal year 2025, PGEN carried roughly $93.17M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Precigen, Inc.'s gross margin?
PGEN's gross margin was 50.2% in fiscal 2025 — gross profit of $4.86M on revenue of $9.68M.
What is Precigen, Inc.'s market cap?
Precigen, Inc. (PGEN) has a market capitalization of about $1.58B, based on the latest data in our nightly-refreshed cache.
When does Precigen, Inc.'s fiscal year end?
PGEN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Precigen, Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.